Exicure, Inc., a biotechnology company, announced the completion of a 1-for-5 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on August 27, 2024. The reverse stock split was approved by stockholders during a Special Meeting held on August 20, 2024, and was subsequently approved by the company's board of directors on the same day. The action consolidates every five shares of issued and outstanding common stock into one share, maintaining the same par value per share without altering the number of authorized shares. This corporate action aims to regain compliance with Nasdaq's listing rules. The company's common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on August 28, 2024, under the new CUSIP...Show More

Exicure, Inc., a biotechnology company, announced the completion of a 1-for-5 reverse stock split of its common stock, effective at 5:00 p.m. Eastern Time on August 27, 2024. The reverse stock split was approved by stockholders during a Special Meeting held on August 20, 2024, and was subsequently approved by the company's board of directors on the same day. The action consolidates every five shares of issued and outstanding common stock into one share, maintaining the same par value per share without altering the number of authorized shares. This corporate action aims to regain compliance with Nasdaq's listing rules. The company's common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on August 28, 2024, under the new CUSIP number 30205M309. Stockholders will not receive fractional shares; instead, they will receive a full share in lieu of any fractional shares, ensuring that stockholders' percentage ownership of the company's common stock remains unchanged, except for adjustments due to fractional shares. The reverse stock split reduces the number of outstanding shares from approximately 8.65 million to approximately 1.73 million. Exicure has historically focused on developing nucleic acid therapies but is currently exploring strategic alternatives to maximize stockholder value following a restructuring and suspension of clinical and development activities.